Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?
2014
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?
- Ist Teil von
- Clinical chemistry (Baltimore, Md.), 2014-10, Vol.60 (10), p.1249-1251
- Ort / Verlag
- England: American Association for Clinical Chemistry, Inc
- Erscheinungsjahr
- 2014
- Quelle
- Oxford Journals 2020 Medicine
- Beschreibungen/Notizen
- According to the results presented in this study, in patients with ovarian cancer, ERCC1^ CTCs consti- tuted an independent predictor for overall and progression-free survival. Preanalytical issues, blood collection systems, and analysis steps should be care- fully standardized and subjected to thorough internal and external quality control systems. [...]valida- tion of clinical utility of CTC analysis assays through defined endpoints, such as overall survival, in multi- center clinical trials is absolutely necessary before their implementation in clinical practice.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0009-9147eISSN: 1530-8561DOI: 10.1373/clinchem.2014.230144Titel-ID: cdi_proquest_miscellaneous_1566820374
- Format
- –
- Schlagworte
- Biology, Biomarkers, Tumor - blood, Biomarkers, Tumor - genetics, Biopsy, Breast Neoplasms - blood, Cancer, Cancer cells, Cancer therapies, Care and treatment, Class I Phosphatidylinositol 3-Kinases, Clinical medicine, Clinical trials, Comparative Genomic Hybridization - methods, Deoxyribonucleic acid, DNA, DNA-Binding Proteins - genetics, Drug Resistance, Neoplasm, Endonucleases - genetics, Female, Genomes, Humans, Metastasis, Methods, Neoplastic Cells, Circulating - metabolism, Ovarian cancer, Ovarian Neoplasms - blood, Patients, Phosphatidylinositol 3-Kinases - genetics, Physiological aspects, Tumor Suppressor Protein p53 - genetics